ArticleJournal of the peripheral nervous system : JPNS2025
Differential Impact of Metabolic Factors and Comorbidities on Peripheral Neuropathy.
Article in Journal of the peripheral nervous system : JPNS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Corneal Confocal Microscopy as a Non-Invasive Marker of Small Fiber Neuropathy and Systemic Complications in Type 2 Diabetes: A Cross-Sectional Study.Biomolecules · 2026Observational
- Increased C-reactive protein is associated with corneal nerve loss and painful neuropathic symptoms in Type 2 diabetes mellitus.Journal of diabetes investigation · 2026Article
- The Association Between Detailed Obesity Measurements and Peripheral Neuropathy in Persons With Diabetes.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveThis study aimed to assess the impact of metabolic factors and comorbidities on peripheral neuropathy.
methodsQatari nationals and long-term residents from the Qatar Biobank underwent clinical/metabolic assessments, including iDXA to measure visceral adipose tissue (VAT) and subcutaneous (SAT) volumes, inflammation, thyroid function, carotid intima media thickness (CIMT), corneal confocal microscopy (CCM), vibration perception threshold (VPT), and DN4 questionnaire.
resultsIn 332 adults aged 43.4 ± 12.7 years, the prevalence of neuropathy was 3.9%. The prevalence of T2D was 16.6%, and the prevalence of neuropathy was significantly higher in T2D (14.5% vs. 1.8%, p < 0.0001). A higher HbA1c (p = 0.05) and lower eGFR (p < 0.01) were associated with reduced inferior whorl length (IWL) and lower FT3 was associated with reduced corneal nerve fiber length (CNFL) (p < 0.01). Triglycerides were associated with increased neuropathic symptoms (p = 0.05). All the risk factors in this study contributed to 39% of neuropathy in T2D but had a minimal impact in those without T2D.
conclusionsThis study highlights the importance of additional risk factors beyond traditional risk factors associated with peripheral neuropathy in T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.